Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

Solene M. Evrard*, Estelle Taranchon-Clermont, Isabelle Rouquette, Samuel Murray, Sebastian Dintner, Yun-Chung Nam-Apostolopoulos, Beatriz Bellosillo, Mar Varela-Rodriguez, Ernest Nadal, Klaus H. Wiedorn, Linea Melchior, Emma Andrew, Mary Jones, Jennifer Ridgway, Christina Frykman, Linda Lind, Mitja Rot, Izidor Kern, Ernst J. M. Speel, Guido M. J. M. RoemenNicol Trincheri, Sandra N. Freiberger, Markus Rechsteiner

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Web of Science)

Abstract

Before initiating treatment of advanced non-small-cell lung cancer with tyrosine kinase inhibitors (eg, erlotinib, gefitinib, osimertinib, and afatinib), which inhibit the catalytic activity of epidermal growth factor receptor (EGFR), clinical guidelines require determining the EGFR mutational status for activating (EGFR exons 18, 19, 20, or 21) and resistance (EGFR exon 20) mutations. The EGFR resistance mutation T790M should be monitored at cancer progression. The Idylla EGFR Mutation Assay, performed on the Idylla molecular diagnostics platform, is a fully automated (

Original languageEnglish
Pages (from-to)1010-1024
Number of pages15
JournalJournal of Molecular Diagnostics
Volume21
Issue number6
DOIs
Publication statusPublished - Nov 2019

Keywords

  • TYROSINE KINASE INHIBITORS
  • GROWTH-FACTOR RECEPTOR
  • MOLECULAR BIOMARKERS
  • DIAGNOSIS
  • ASSOCIATION
  • PATHOLOGY

Cite this